{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=57",
    "query": {
      "intervention": "Control Study Product",
      "page": 57
    },
    "page_size": 10
  },
  "pagination": {
    "page": 57,
    "page_size": 10,
    "total_count": 4237,
    "total_pages": 424,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=58&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=56&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T15:00:30.726Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02170298",
      "title": "Lisdexamfetamine's Effect In ADHD in the Brain and Cognition",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Lisdexamfetamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Years to 30 Years"
      },
      "enrollment_count": 6,
      "start_date": "2014-02",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2019-12-26",
      "last_synced_at": "2026-10-29T15:00:30.726Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02170298"
    },
    {
      "nct_id": "NCT07470463",
      "title": "Evaluation of One-Shot Vision Differential Diagnosis (OSVDE) and Multi-Step Conversational Non-Inferiority (MSCNE) in AI Medical Interviewing",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Differential Diagnosis",
        "Diagnostic Accuracy"
      ],
      "interventions": [
        {
          "name": "AI Diagnostic System (AIMD.1)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Magic Health Inc. (d.b.a. Nolla Health)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-03-19",
      "completion_date": "2026-09-19",
      "has_results": false,
      "last_update_posted_date": "2026-03-25",
      "last_synced_at": "2026-10-29T15:00:30.726Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07470463"
    },
    {
      "nct_id": "NCT06891547",
      "title": "Radicle Spark for Women™ 24: Assessing the Impact of Health and Wellness Products on Sexual Health and Related Health Outcomes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sexual Satisfaction",
        "Sexual Function"
      ],
      "interventions": [
        {
          "name": "Spark Placebo Control 5.1",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Spark Active Study Product 5.1 Usage",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Radicle Science",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "105 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 105 Years · Female only"
      },
      "enrollment_count": 600,
      "start_date": "2025-02-20",
      "completion_date": "2025-08-11",
      "has_results": false,
      "last_update_posted_date": "2025-08-15",
      "last_synced_at": "2026-10-29T15:00:30.726Z",
      "location_count": 1,
      "location_summary": "Del Mar, California",
      "locations": [
        {
          "city": "Del Mar",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06891547"
    },
    {
      "nct_id": "NCT03339258",
      "title": "A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stress Disorders, Post-Traumatic"
      ],
      "interventions": [
        {
          "name": "Doxazosin Mesylate, Extended Release",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "San Francisco Veterans Affairs Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 80,
      "start_date": "2018-04-15",
      "completion_date": "2024-06",
      "has_results": false,
      "last_update_posted_date": "2024-05-01",
      "last_synced_at": "2026-10-29T15:00:30.726Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03339258"
    },
    {
      "nct_id": "NCT02611804",
      "title": "A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Actinic Keratosis"
      ],
      "interventions": [
        {
          "name": "Diclofenac sodium",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 492,
      "start_date": "2015-10",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2017-05-05",
      "last_synced_at": "2026-10-29T15:00:30.726Z",
      "location_count": 30,
      "location_summary": "Mesa, Arizona • Tucson, Arizona • Fremont, California + 23 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02611804"
    },
    {
      "nct_id": "NCT03020784",
      "title": "Safety and Tolerability of PF-06818883 in Healthy Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "PF-06818883",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2016-11-11",
      "completion_date": "2017-06-13",
      "has_results": false,
      "last_update_posted_date": "2017-12-11",
      "last_synced_at": "2026-10-29T15:00:30.726Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03020784"
    },
    {
      "nct_id": "NCT06273852",
      "title": "A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Soft Tissue Sarcoma Adult",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "PBA-0405",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pure Biologics S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2024-04-29",
      "completion_date": "2025-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-11",
      "last_synced_at": "2026-10-29T15:00:30.726Z",
      "location_count": 4,
      "location_summary": "Shreveport, Louisiana • Portland, Oregon • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06273852"
    },
    {
      "nct_id": "NCT02618343",
      "title": "EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nausea"
      ],
      "interventions": [
        {
          "name": "IPA",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 51,
      "start_date": "2016-10-04",
      "completion_date": "2019-03-01",
      "has_results": true,
      "last_update_posted_date": "2021-03-24",
      "last_synced_at": "2026-10-29T15:00:30.726Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02618343"
    },
    {
      "nct_id": "NCT04565015",
      "title": "Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immune Deficiency"
      ],
      "interventions": [
        {
          "name": "GC5107",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GC Biopharma Corp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "2 Years to 16 Years"
      },
      "enrollment_count": 24,
      "start_date": "2020-12-21",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2025-07-25",
      "last_synced_at": "2026-10-29T15:00:30.726Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Centennial, Colorado • Dallas, Texas + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04565015"
    },
    {
      "nct_id": "NCT00983255",
      "title": "Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "TR-701 FA for injection, 200 mg/vial",
          "type": "DRUG"
        },
        {
          "name": "TR-701 FA tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 90,
      "start_date": "2009-09",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2016-05-19",
      "last_synced_at": "2026-10-29T15:00:30.726Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00983255"
    }
  ]
}